Influenza vaccine formulation

Details Influenza vaccine formulation Influenza vaccine formulation

2007-11-30

2010-10-05

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S185100, C530S300000, C530S326000

Reexamination Certificate

active

07807173

ABSTRACT:
Peptide-based anti-influenza formulations against influenza are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza, particularly avian influenza.

REFERENCES:
patent: 2002/0183484 (2002-12-01), Torres
patent: 2004/0223976 (2004-11-01), Bianchi et al.
patent: 03/066090 (2003-08-01), None
patent: 2006/128294 (2007-05-01), None
patent: 2007056266 (2007-05-01), None
patent: WO 2007/051036 (2007-05-01), None
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Crowe et al.,“Identification of protective and non-protective T cell epitopes in influenza,” Vaccine, vol. 24 No. 4, pp. 452-456 (Jan. 2006).
GenPept ABJ51684, “hemagglutinin [Influenza A virus (A/chicken/Viet Nam/11/2005(H5N1))],” Oct. 2006.
GenPept ABJ96856, “hemagglutinin [Influenza A virus, (A/goose/Shantou/2104/2006(H5N1))],” Oct. 2006.
Hioe et al., “Overlapping cytotoxic T-lymphocyte and B-cell antigenic sites on the influenza virus H5 hemagglutinin,” Journal of Virology, vol. 64 No. 12, pp. 6246-6251 (Dec. 1990).
Mateu et al., “A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C,” Journal of General Virology, vol. 71 No. 3, pp. 629-637 (Mar. 1990).
Riffkin et al., “A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 from Dichelobacter nodosus,” Gene, vol. 167 Nos. 1-2, pp. 179-283 (Dec. 1995).
Ha et al., “X-ray structure of H5 avian and H9 swine influenza virus hemagglutinins bound to avian and human receptor analogs”, Proc. National Acad. Science USA, Sep. 25, 2001, vol. 98, No. 20, pp. 11181-11186.
Kaverin et al., “Structure of antigenic sites on the hemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants”, Journal Gen. Virology, Oct. 2002, vol. 83, Pt. 10, pp. 2497-2505.
Katz et al. “Pathogenesis of and immunity to avian influenza A H5 viruses”, Biomedicine and Pharmacotherapy, Elsevier, Paris, Fr., vol. 54, No. 4, May 1, 2000, pp. 178-187 XP005888635.
European Patent Application No. 07855446.6: Extended European Search Report dated Jan. 26, 2010.

Affiliated with

Also associated with

Rating

Influenza vaccine formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Influenza vaccine formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza vaccine formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4240252